Specialty drugs: a distinctly American phenomenon

Huseyin Naci and Aaron S. Kesselheim

LSE Research Online Documents on Economics from London School of Economics and Political Science, LSE Library

Abstract: Various stakeholders in the pharmaceutical supply chain assign the specialty label to drugs on the basis of a combination of several unrelated factors, including whether a drug treats a rare condition. But the single most common feature of specialty drugs is high cost.

Keywords: Cost Sharing/economics; Cost-Benefit Analysis; Drug Costs/legislation & jurisprudence; Drug Industry/legislation & jurisprudence; Government Regulation; Humans; Insurance Coverage/economics; Insurance; Pharmaceutical Services/economics; Medicaid/economics; Medicare Part D/economics; Patient Protection and Affordable Care Act; Pharmaceutical Preparations/economics; Rare Diseases/drug therapy; United States (search for similar items in EconPapers)
JEL-codes: J1 (search for similar items in EconPapers)
Pages: 3 pages
Date: 2020-06-04
New Economics Papers: this item is included in nep-ias and nep-ore
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Published in New England Journal of Medicine, 4, June, 2020, 382(23), pp. 2179 - 2181. ISSN: 0028-4793

Downloads: (external link)
http://eprints.lse.ac.uk/105102/ Open access version. (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ehl:lserod:105102

Access Statistics for this paper

More papers in LSE Research Online Documents on Economics from London School of Economics and Political Science, LSE Library LSE Library Portugal Street London, WC2A 2HD, U.K.. Contact information at EDIRC.
Bibliographic data for series maintained by LSERO Manager ().